An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers

[1] Ellis MJ(2008)Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 1380-1388

[2] Tao Y(2009)New response evaluation criteria in solid tumours: revised RECIST guideline. Version 1.1. Eur J Cancer 45 228-247

[3] Luo J(2007)Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 167-170

[4] A’Hern R(2020)ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment Tumour Biol 42 1010428320925301-4065

[5] Evans DB(2017)NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer Clin Cancer Res 23 4055-189

[6] Bhatnagar AS(2019)Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial J Clin Oncol 37 178-241

[7] Eisenhauer EA(2016)Clinical relevance of host immunity in breast cancer: from TILs to the clinic Nat Rev Clin Oncol 13 228-2186

[8] Therasse P(2020)Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis BMC Womens Health 20 194-50

[9] Bogaerts J(2019)Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer Oncol Lett 17 2177-302

[10] Schwartz LH(2018)Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Lancet Oncol 19 40-145

[1] Ellis MJ(2008)Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 1380-1388

[2] Tao Y(2009)New response evaluation criteria in solid tumours: revised RECIST guideline. Version 1.1. Eur J Cancer 45 228-247

[3] Luo J(2007)Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 167-170

[4] A’Hern R(2020)ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment Tumour Biol 42 1010428320925301-4065

[5] Evans DB(2017)NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer Clin Cancer Res 23 4055-189

[6] Bhatnagar AS(2019)Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial J Clin Oncol 37 178-241

[7] Eisenhauer EA(2016)Clinical relevance of host immunity in breast cancer: from TILs to the clinic Nat Rev Clin Oncol 13 228-2186

[8] Therasse P(2020)Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis BMC Womens Health 20 194-50

[9] Bogaerts J(2019)Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer Oncol Lett 17 2177-302

[10] Schwartz LH(2018)Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Lancet Oncol 19 40-145